Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validating Candin Challenge with Belimumab
NCT04611971Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belimumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Presence and Size of Induration at Day 8. Started Oct 2020; status: completed.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04611971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611971.